Succinyl-β-cyclodextrin modified gold biochip improved seroimmunological detection sensitivity for Lyme disease

Area of Science:

• Biotechnology
• Immunodiagnostics
• Materials Science

Background:

• Cyclodextrins (CDs) are cyclic oligosaccharides known for host-guest interactions with hydrophobic molecules.
• CDs are utilized in capillary electrophoresis and pharmaceutical engineering.
• Sensitive serological detection of Lyme disease is crucial for timely diagnosis and treatment.

Purpose of the Study:

• To develop a succinyl-β-cyclodextrin (CD) modified gold biochip for enhanced Lyme disease seroimmunological detection.
• To evaluate the affinity, sensitivity, and specificity of the modified biochip for VlsE protein and anti-VlsE IgG antibody detection.

Main Methods:

• Fabrication of a gold biochip modified with succinyl-β-cyclodextrin.
• Assessment of VlsE protein immobilization and antigen-antibody interactions using fluorescence-based assays.
• Specificity confirmation via immunological block assay and comparison with ELISA (Enzyme-Linked Immunosorbent Assay).

Main Results:

• The succinyl-β-CD modified biochip exhibited enhanced affinity for VlsE protein, with a sensitive detection limit of 0.39 μg/mL for anti-VlsE IgG antibody.
• The biochip demonstrated high specificity for VlsE, confirmed by block assays.
• A strong correlation (R² = 0.904) was observed between the biochip assay and ELISA, suggesting comparable performance.

Conclusions:

• The succinyl-β-CD modified gold biochip offers a sensitive and specific platform for Lyme disease serological detection targeting VlsE.
• This biochip-based assay presents a promising alternative to traditional ELISA methods for Lyme disease diagnostics.
• The platform is not suitable for flagellin and OspC detection.